PURPOSE: To evaluate trends in fractionation and cost of radiation for bone metastasis during a time period of multiple national quality improvement initiatives that focused on reducing the number of fractions per radiation episode. METHODS: Using nationwide Medicare claims from 2011 to 2014, we identified radiation episodes for bone metastasis from prostate, lung, and breast cancer. Details regarding fractionation, radiation therapy (RT) modality, and sociodemographic characteristics were abstracted from claims. Time trends in use of 10 or fewer RT fractions per episode were evaluated using the Cochran-Armitage test. Total cost per episode was calculated from a payer's perspective and reported in 2017 dollars; time trends in cost were assessed using linear regression. Generalized linear models identified predictors of treatment with 10 or fewer fractions. RESULTS: Of 51,533 episodes identified, 46,326 used 2D/3D RT, 3,199 used intensity-modulated RT, and 2,008 used stereotactic body RT. The proportion of 2D/3D RT episodes using 10 or fewer fractions increased from 65.5% to 79.7% ( Ptrend < .001), and mean total cost per episode decreased from $6,742 to $6,067 ( Ptrend < .001). Use of single-fraction radiation increased modestly for 2D/3D treatment (6.5% to 8.1%; Ptrend < .001). Predictors of 10 or fewer fractions included treatment in recent years, advanced age (≥ 85 years), and higher comorbidity score. Variation was noted based on geographic region and primary cancer. CONCLUSION: During a period with quality initiatives launched by the American Society for Radiation Oncology, American Board of Internal Medicine, and National Quality Forum, use of 10 or fewer fractions for bone metastasis increased by 14.2%, but single-fraction regimens increased by only 1.6%, highlighting opportunities for quality improvement.
PURPOSE: To evaluate trends in fractionation and cost of radiation for bone metastasis during a time period of multiple national quality improvement initiatives that focused on reducing the number of fractions per radiation episode. METHODS: Using nationwide Medicare claims from 2011 to 2014, we identified radiation episodes for bone metastasis from prostate, lung, and breast cancer. Details regarding fractionation, radiation therapy (RT) modality, and sociodemographic characteristics were abstracted from claims. Time trends in use of 10 or fewer RT fractions per episode were evaluated using the Cochran-Armitage test. Total cost per episode was calculated from a payer's perspective and reported in 2017 dollars; time trends in cost were assessed using linear regression. Generalized linear models identified predictors of treatment with 10 or fewer fractions. RESULTS: Of 51,533 episodes identified, 46,326 used 2D/3D RT, 3,199 used intensity-modulated RT, and 2,008 used stereotactic body RT. The proportion of 2D/3D RT episodes using 10 or fewer fractions increased from 65.5% to 79.7% ( Ptrend < .001), and mean total cost per episode decreased from $6,742 to $6,067 ( Ptrend < .001). Use of single-fraction radiation increased modestly for 2D/3D treatment (6.5% to 8.1%; Ptrend < .001). Predictors of 10 or fewer fractions included treatment in recent years, advanced age (≥ 85 years), and higher comorbidity score. Variation was noted based on geographic region and primary cancer. CONCLUSION: During a period with quality initiatives launched by the American Society for Radiation Oncology, American Board of Internal Medicine, and National Quality Forum, use of 10 or fewer fractions for bone metastasis increased by 14.2%, but single-fraction regimens increased by only 1.6%, highlighting opportunities for quality improvement.
Authors: Lowell E Schnipper; Thomas J Smith; Derek Raghavan; Douglas W Blayney; Patricia A Ganz; Therese Marie Mulvey; Dana S Wollins Journal: J Clin Oncol Date: 2012-04-03 Impact factor: 44.544
Authors: Sanders Chang; Peter May; Nathan E Goldstein; Juan Wisnivesky; Kenneth Rosenzweig; R Sean Morrison; Kavita V Dharmarajan Journal: J Palliat Med Date: 2017-11-30 Impact factor: 2.947
Authors: Sonia Skamene; Isha Agarwal; Maggie Makar; Monica Krishnan; Alex Spektor; Lauren Hertan; Kent W Mouw; Allison Taylor; Sarah Noveroske Philbrick; Tracy Balboni Journal: Ann Palliat Med Date: 2017-11-30
Authors: Carol Hahn; Brian Kavanagh; Ajay Bhatnagar; Geraldine Jacobson; Stephen Lutz; Caroline Patton; Louis Potters; Michael Steinberg Journal: Pract Radiat Oncol Date: 2014 Nov-Dec
Authors: Drew Moghanaki; Alice V Cheuk; Helen Fosmire; Mitchell S Anscher; Stephen T Lutz; Michael P Hagan; George A Dawson Journal: J Palliat Med Date: 2014-09-04 Impact factor: 2.947
Authors: Shayna E Rich; Ronald Chow; Srinivas Raman; K Liang Zeng; Stephen Lutz; Henry Lam; Maurício F Silva; Edward Chow Journal: Radiother Oncol Date: 2018-02-01 Impact factor: 6.280
Authors: Yolanda D Tseng; Nathan W Gouwens; Simon S Lo; Lia M Halasz; Phil Spady; Irina Mezheritsky; Elizabeth Loggers Journal: Int J Radiat Oncol Biol Phys Date: 2018-01-31 Impact factor: 7.038
Authors: Patricia Mae G Santos; Kaitlyn Lapen; Zhigang Zhang; Stephanie Lobaugh; C Jillian Tsai; T Jonathan Yang; Justin E Bekelman; Erin F Gillespie Journal: Int J Radiat Oncol Biol Phys Date: 2020-11-12 Impact factor: 7.038
Authors: Benjamin A Y Cher; Michael Dykstra; Chang Wang; Matthew Schipper; James A Hayman; Charles S Mayo; Reshma Jagsi Journal: Adv Radiat Oncol Date: 2022-07-22
Authors: Erin F Gillespie; Kaitlyn Lapen; Diana G Wang; N Wijetunga; Gerri L Pastrana; Marisa A Kollmeier; Josh Yamada; Adam M Schmitt; Daniel S Higginson; Max Vaynrub; Ernesto Santos Martin; Amy J Xu; C Tsai; Divya Yerramilli; Oren Cahlon; T Yang Journal: Clin Transl Radiat Oncol Date: 2020-10-08
Authors: Robert A Olson; Vincent LaPointe; Alex Benny; Matthew Chan; Shilo Lefresne; Michael McKenzie Journal: Curr Oncol Date: 2022-03-18 Impact factor: 3.677
Authors: Tamara Fogarty; Mark Tacey; Giulia McCorkell; David Kok; Colin Hornby; Roger L Milne; Jeremy Millar; Farshad Foroudi; Wee Loon Ong Journal: J Med Imaging Radiat Oncol Date: 2022-02-01 Impact factor: 1.667